Treatment of CPVT in a Genetically Positive, Asymptomatic Carrier with No Documented Ventricular Arrhythmia

Managing catecholaminergic polymorphic ventricular tachycardia (CPVT) in individuals who carry a confirmed pathogenic mutation but have never had symptoms, documented arrhythmia, or an aborted cardiac arrest requires a carefully calibrated approach — distinct from management in phenotypically expressed disease.

Clinical scenario

Confirmed pathogenic mutation in a CPVT disease-causing gene
Asymptomatic — no exercise- or stress-triggered ventricular arrhythmia documented
No history of aborted cardiac arrest

Management approach

Even in the absence of a documented phenotype, current evidence supports active intervention in this genotype-positive subgroup. The full protocol outlines the role of device-based therapy and a surgical autonomic procedure in this setting — including the specific criteria, decision sequence, and conditions under which each applies.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehac262

It is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes.

Therapy with beta-blockers should be considered for genetically positive CPVT patients without phenotype.

This panel has confirmed the indication to treat genetically positive family members with beta-blockers, even in the absence of documented exercise- or stress-induced VAs.

ICD implantation should be considered in patients with CPVT who experience arrhythmogenic syncope and/or documented bidirectional/PVT while on highest tolerated beta-blocker dose and on flecainide.

LCSD should be considered in patients with diagnosis of CPVT when the combination of beta-blockers and flecainide at therapeutic dosage are either not effective, not tolerated, or contraindicated.

View source ↗